Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas

Abstract: Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor (CAR)–modified T cells (CAR-T). The optimal timing of BsAbs and biomarkers of BsAb response after CAR-T are unknown. We...

Full description

Saved in:
Bibliographic Details
Main Authors: Elise A. Chong, Elicia Penuel, Ellen B. Napier, Rachel K. Lundberg, Lihua E. Budde, Mazyar Shadman, Matthew J. Matasar, Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R. Chong, Stephen J. Schuster
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924006724
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952924006724

Similar Items